December 28, 2014 5:35 AM ET

Biotechnology

Company Overview of LipoScience, Inc.

Company Overview

LipoScience, Inc., a clinical diagnostic company, is engaged in the field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology in the United States. The company’s technology platform combines proprietary signal processing algorithms and NMR spectroscopic detection into a clinical analyzer to identify and quantify concentrations of lipoproteins and small molecule metabolites. It offers NMR LipoProfile test, which directly measures various low density lipoprotein (LDL) particles in a blood sample, and provides physicians and their patients with information to personalize management of risk for heart disease. LipoScience, Inc. sells its NMR LipoProfile test to clinic...

2500 Sumner Boulevard

Raleigh, NC 27616

United States

Founded in 1994

239 Employees

Phone:

919-212-1999

Key Executives for LipoScience, Inc.

Chief Executive Officer
Age: 53
Founder
Age: 66
Chief Financial Officer
Age: 60
Vice President
Age: 51
Chief Medical Officer
Age: 52
Compensation as of Fiscal Year 2014.

LipoScience, Inc. Key Developments

LipoScience, Inc.(NasdaqGM:LPDX) dropped from NASDAQ Composite Index

LipoScience, Inc. will be removed from the NASDAQ Composite Index.

LipoScience, Inc. Announces Financial Results for the Third Quarter and Nine Months Ended September 30, 2014

LipoScience, Inc. announced financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenues of $8,562,000 against $12,738,000 a year ago. Loss from operations was $3,832,000 against $4,179,000 a year ago. Net loss was $4,260,000 against $4,627,000 a year ago. Net loss per basic and diluted share was $0.28 against $0.31 a year ago. Net cash used in operating activities was $1.9 million for the three months ended September 30, 2014, a decrease of $0.3 million from the same period last year. For the nine months, the company reported revenues of $29,615,000 against $39,665,000 a year ago. Loss from operations was $9,070,000 against $8,506,000 a year ago. Net loss was $10,359,000 against $9,919,000 a year ago. Net loss per basic and diluted share was $0.68 against $0.67 a year ago. Net cash used in operating activities was $5,444,000 against $9,007,000 a year ago. Purchases of property and equipment were $4,525,000 against $2,939,000 a year ago. Capitalized patent and trademark costs were $48,000 against $154,000 a year ago.

LipoScience, Inc., Special/Extraordinary Shareholders Meeting, Nov 20, 2014

LipoScience, Inc., Special/Extraordinary Shareholders Meeting, Nov 20, 2014. Agenda: To consider and adopt the agreement and plan of merger.

Similar Private Companies By Industry

Company Name Region
CoDa Therapeutics, Inc. United States
Viragen International, Inc. United States
Aprogenex, Inc. United States
ISTO Technologies, Inc. United States
BioDetego LLC United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 25, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LipoScience, Inc., please visit www.liposcience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.